^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anal Carcinoma

    2d
    The Role of Pyroptosis in Colorectal Cancer: From Mechanisms to Therapeutic Opportunities. (PubMed, Cancer Manag Res)
    The pyroptosis therapy in colorectal cancer involves the drug, natural-occurring substances, chemotherapy, nanotechnology, radiotherapy, virus, and other novel treatments such as photodynamic therapy (PDT). This article explores the mechanisms of pyroptosis and its research on colorectal cancer detection and prognosis, focusing on the research related to pyroptosis and colorectal treatment, and provides an outlook on the future of pyroptosis and colorectal cancer treatment.
    Review • Journal
    |
    NLRP3 (NLR Family Pyrin Domain Containing 3) • GSDME (Gasdermin E)
    4d
    Anal Phyllodes Tumor in a Man: An Exceptionally Rare Case Report and Literature Review. (PubMed, Int J Surg Pathol)
    This rare tumor highlights that phyllodes tumors can occur in the anogenital region of men and emphasizes the importance of distinguishing them from other anal tumors. Long-term follow-up is recommended after resection.
    Journal
    |
    ER (Estrogen receptor) • CD34 (CD34 molecule) • GATA3 (GATA binding protein 3)
    6d
    GOBLET: A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab (clinicaltrials.gov)
    P1/2, N=122, Recruiting, Oncolytics Biotech
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • Reolysin (pelareorep)
    8d
    a-HPVVIH: Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV (clinicaltrials.gov)
    P=N/A, N=398, Recruiting, Centre Hospitalier Universitaire de la Réunion | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2026 --> Dec 2026
    Enrollment open • Trial primary completion date
    8d
    Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC (clinicaltrials.gov)
    P=N/A, N=462, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | N=720 --> 462
    Trial completion • Enrollment change
    9d
    ULACNet-104: Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH) (clinicaltrials.gov)
    P=N/A, N=217, Completed, University of California, San Francisco | Recruiting --> Completed | N=100 --> 217 | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: May 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    15d
    HPVsign: Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, ANRS, Emerging Infectious Diseases | Not yet recruiting --> Recruiting
    Enrollment open
    21d
    SCAN-LITE: Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening (clinicaltrials.gov)
    P=N/A, N=101, Active, not recruiting, Massachusetts Eye and Ear Infirmary | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Jan 2026 | Trial primary completion date: Jul 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    21d
    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    22d
    Immunodeficiency, HIV Viremia, and Incident Anal Cancer Among People With HIV in South Africa. (PubMed, Open Forum Infect Dis)
    Lower CD4 counts and, to a lesser extent, higher HIV RNA viral loads were associated with an increased anal cancer risk. Maintaining high CD4 counts may contribute to anal cancer prevention among PWH in South Africa.
    Journal
    |
    CD4 (CD4 Molecule)
    24d
    Prognostic analysis of local excision in 153 cases of locally advanced low rectal cancer following neoadjuvant therapy (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
    At 1 year after surgery, 10 cases (10.5%, 10/95) had severe anal dysfunction, and the median LARS score of the entire group was 5.0 (range: 0-41.0) points. For patients with locally advanced low rectal cancer who achieve cCR or near-cCR after neoadjuvant therapy, local excision results in favorable oncological prognosis and anal function preservation effects; however, the incidence of complications is relatively high.
    Retrospective data • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    25d
    Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients. (PubMed, NPJ Precis Oncol)
    Four clinical examples illustrated LB-guided therapies. This largest-to-date aSCC cohort reinforces molecular profiling-especially LB-as a key tool for guiding personalized therapy.
    Journal • Liquid biopsy • Tumor mutational burden • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • KMT2D (Lysine Methyltransferase 2D) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    TP53 mutation • EGFR mutation • TMB-H • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • FGFR2 mutation
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx